Most Recent Articles by Douglas Strassler
Different clinical and neurobiologic pathways may be involved in treatment-resistant schizophrenia as it is not a homogeneous subgroup within the schizophrenia spectrum.
For patients with bipolar disorder and major depressive disorder, reduction in dose of antipsychotic medication could lead to an increased rate of hospitalization.
Augmentation therapy for treatment-resistant major depressive disorder includes multiple options with different strengths and limitations.
Children who are diagnosed on the autism spectrum are protected by their parents and community and are not properly actualized.
Updates made to the DSM-5 will clarify the diagnosis of bipolar disorder and related disorders.
More Articles by Douglas Strassler
Psychiatry Advisor Articles
- ADHD, Comorbid Bipolar Disorder Share Similar Neurocognitive Profiles
- Anxiety Prevention Interventions: How Effective Are They?
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Hypertension Linked to an Increased Risk of Dementia?
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Maternal Glucocorticoid Exposure Not Associated With ADHD in Offspring
- Ketamine Not Associated With PTSD Development in Military Trauma Setting
- Content, Quality Issues for Both Paper-Based and Electronic Health Records